Edwin is a healthcare journalist with a passion for data and analysis. He graduated with a master's degree in biomedical sciences and spent some time in postgraduate research before moving into journalism. Edwin's skills in data science and scientific analysis allow him to identify trends, develop insights, and tell compelling stories using data.
Latest from Edwin Elmhirst
Two familiar heavyweights of the obesity field return for another match, while four smaller companies are tipped to bring their own blockbusters to market, new data from Evaluate Pharma show.
Investor enthusiasm for exciting data in 2025 transformed the prospects of a few companies in a single day’s trading – but that enthusiasm sometimes disappeared almost as quickly as it arrived.
Investor enthusiasm for exciting data in 2025 transformed the prospects of a few companies in a single day’s trading – but that enthusiasm sometimes disappeared almost as quickly as it arrived.
The pharmaceutical industry continues to experience significant shifts in sales performance, with some companies achieving remarkable growth while others face stagnation or decline.
In Vivo looks at the therapies projected to lead global sales by 2030. These frontrunners not only reflect advances in innovation but also shifting priorities in chronic disease management.
As blockbuster drugs lose patent protection and sales decline, big pharma companies must replenish aging portfolios with innovative therapies. Some, like Eli Lilly and Novo Nordisk, are rising through new drug launches while others are increasingly reliant on older assets.